Overview
Reviews the interplay of the glutamatergic system with other neurotransmitters & neurotrophic factors in CNS diseases
Individual chapters deal with the neuropathophysiology and glutamate-based treatment options of a specific CNS disease
Presents translational principles used in the development of CNS glutamate-based therapeutic modalities
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (20 chapters)
-
Front Matter
Keywords
- Aggression
- Alzheimer's Disease
- Amyotrophic Lateral Sclerosis
- Attention Deficit Hyperactivity Disorder
- Autism Spectrum Disease
- Bipolar Disorders
- Chronic Pain
- Chronic Stress and Resilience
- Drug Development
- Epilepsy
- Glutamate Signaling
- Ischemic Stroke
- Migraine
- Multiple Sclerosis
- Parkinson's Disease
- Psychopharmacology
- Schizophrenia
About this book
This volume provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It draws on the latest findings in glutamate neurobiology and offers valuable insights into the application of translational principles in neuroscience drug discovery and development.
In each chapter, glutamate as a neurotransmitter, its receptors and transporters, and their interplay with other neurotransmitters and neurotrophic factors, are discussed in the context of a specific, highly prevalent and disabling CNS disease. Most recent and detailed information is provided on Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer’s Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders. Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines.
The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence.
Editors and Affiliations
About the editor
Dr. Zoran M. Pavlovic focuses his work on consulting pharmaceutical and biotech companies on clinical trial design, methodology, biomarkers and surrogate endpoints, patient-reported outcomes, and psychometric assessments, related to development of their drug candidates for treatment of major psychiatric and neurological disorders.
Dr. Pavlovic’s primary interests and expertise have centered on psychopharmacologic approaches to Chronic Stress, Major Depressive and Anxiety disorders, Substance Use Disorders, and Neurodegenerative Disorders.
Dr Pavlovic is the Editorial Board Member for Neuropsychiatric Disease and Treatment journal and Innovations in Clinical Neuroscience, and is the author of numerous scientific articles published in most eminent psychiatric, neuropsychiatric and psychopharmacological journals, such as the Official Journal of the American Neuropsychiatric Association, Official Journal of the European Psychiatric Association and the Official Journal of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). Furthermore, Dr Pavlovic is the editor of the book “Modulators of Glutamatergic Signaling as Potential Treatments for Neuropsychiatric Disorders,” which was published in 2015 by Nova Science Publishers.
Bibliographic Information
Book Title: Glutamate and Neuropsychiatric Disorders
Book Subtitle: Current and Emerging Treatments
Editors: Zoran M. Pavlovic
DOI: https://doi.org/10.1007/978-3-030-87480-3
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Nature Switzerland AG 2022
Hardcover ISBN: 978-3-030-87479-7Published: 11 April 2022
Softcover ISBN: 978-3-030-87482-7Published: 12 April 2023
eBook ISBN: 978-3-030-87480-3Published: 10 April 2022
Edition Number: 1
Number of Pages: XXXV, 600
Number of Illustrations: 3 b/w illustrations, 40 illustrations in colour
Topics: Neurosciences, Neurology, Neuropsychology, Pharmacology/Toxicology, Psychiatry